Search Results - M V Zhuravleva

Refine Results
  1. 1
    DOSTOINSTVA I NEDOSTATKI SOVREMENNYKh NESTEROIDNYKh PROTIVOVOSPALITEL'NYKh PREPARATOV

    DOSTOINSTVA I NEDOSTATKI SOVREMENNYKh NESTEROIDNYKh PROTIVOVOSPALITEL'NYKh PREPARATOV by M V Zhuravleva, T H Aleeva

    Published 2005-06-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Methodology for Creating a Risk Management System for Drug-Drug Interactions

    Methodology for Creating a Risk Management System for Drug-Drug Interactions by A. A. Taube, M. V. Zhuravleva

    Published 2024-03-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease and resistant hypertension

    Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mo... by M. V. Zhuravleva, Yu. V. Gagarina, T. V. Marin

    Published 2025-05-01
    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    EXPERIENCE OF ORNITHINE ASPARTATE (HEPA-MERZ) AND PROBIOTICS BIOFLORUM FORTE IN THE TREATMENT OF NON-SEVERE FORMS OF ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER DISEASE

    EXPERIENCE OF ORNITHINE ASPARTATE (HEPA-MERZ) AND PROBIOTICS BIOFLORUM FORTE IN THE TREATMENT OF NON-SEVERE FORMS OF ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER DISEASE by L. Yu. Ilchenko, L. I. Melnikova, M. V. Zhuravleva

    Published 2016-10-01
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases"

    The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Car... by M. V. Zhuravleva, A. V. Panov, A. R. Kuksenok

    Published 2022-03-01
    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings

    Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings by M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin

    Published 2022-07-01
    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction

    Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mor... by M. V. Zhuravleva, S. V. Nedogoda, Yu. V. Gagarina, T. V. Marin

    Published 2024-08-01
    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Rome IV criteria of functional gastrointestinal diseases in evaluation of drugs interchangeability: through the eyes of a clinical pharmacologist

    Rome IV criteria of functional gastrointestinal diseases in evaluation of drugs interchangeability: through the eyes of a clinical pharmacologist by S. Yu. Serebrova, A. B. Prokofiev, M. V. Zhuravleva, N. N. Eremenko

    Published 2018-02-01
    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Moscow

    Development of methodological approaches to the formation of a risk-based model to minimize the prevalence of adverse reactions in drug application in medical organizations of Mosc... by E. V. Kuznetsova, M. V. Zhuravleva, I. A. Mikhailov, T. I. Kurnosova

    Published 2023-07-01
    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia

    Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia by A. A. Taube, T. V. Alexandrova, O. A. Demidova, M. V. Zhuravleva

    Published 2023-11-01
    Get full text
    Article

    Save to List
    Saved in:
  11. 11
    RETROSPECTIVE ANALYSIS OF REPORTED CASE OF ADVERSE DRUG REACTION - NEUROLEPTIC MALIGNANT SYNDROME ON THE USE OF HALOPERIDOL

    RETROSPECTIVE ANALYSIS OF REPORTED CASE OF ADVERSE DRUG REACTION - NEUROLEPTIC MALIGNANT SYNDROME ON THE USE OF HALOPERIDOL by V. V. Arkhipov, N. G. Berdnikova, M. V. Zhuravleva, V. G. Kukes

    Published 2018-02-01
    Get full text
    Article

    Save to List
    Saved in:
  12. 12
    Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy

    Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy by M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina

    Published 2023-07-01
    Get full text
    Article

    Save to List
    Saved in:
  13. 13
    Potential Possibilities of Monitoring the Procalcitonin Concentration During Antibacterial Therapy of Lower Respiratory Tract Infections

    Potential Possibilities of Monitoring the Procalcitonin Concentration During Antibacterial Therapy of Lower Respiratory Tract Infections by N. B. Lazareva, M. V. Zhuravleva, A. B. Prokofiev, E. V. Shikh

    Published 2020-05-01
    Get full text
    Article

    Save to List
    Saved in:
  14. 14
    Assessment of The Toxicological Profile of The New Dioxidine Dosage Form (Solution for Topical and External Use, 0.025%)

    Assessment of The Toxicological Profile of The New Dioxidine Dosage Form (Solution for Topical and External Use, 0.025%) by M. V. ZHURAVLEVA, E. A. ROSHCHINA, C. A. LOSEVA, A. V. GUROV

    Published 2022-11-01
    Get full text
    Article

    Save to List
    Saved in:
  15. 15
    Strategy and Control of Antimicrobial Therapy Program Implementation at the B.V. Petrovsky National Research Center of Surgery

    Strategy and Control of Antimicrobial Therapy Program Implementation at the B.V. Petrovsky National Research Center of Surgery by M. A. Chukina, N. V. Vistovskaya, M. V. Lukina, M. V. Zhuravleva

    Published 2020-12-01
    Get full text
    Article

    Save to List
    Saved in:
  16. 16
    Clinical and Pharmacological Aspects of Resistance to Eradication Therapy of Helicobacter Pylori Infection

    Clinical and Pharmacological Aspects of Resistance to Eradication Therapy of Helicobacter Pylori Infection by S. Yu. Serebrova, A. B. Prokofiev, N. N. Eremenko, M. V. Zhuravleva, T. A. Alexandrova

    Published 2020-05-01
    Get full text
    Article

    Save to List
    Saved in:
  17. 17
    Effects of ticagrelor in patients with acute coronary syndrome on the targets of the national cardiovascular program

    Effects of ticagrelor in patients with acute coronary syndrome on the targets of the national cardiovascular program by M. V. Zhuravleva, S. K. Zyryanov, F. N. Paleev, V. A. Kotrovsky, T. V. Marin

    Published 2020-06-01
    Get full text
    Article

    Save to List
    Saved in:
  18. 18
    Safety of Herbal Medicines: Clinical and Pharmacological Aspects

    Safety of Herbal Medicines: Clinical and Pharmacological Aspects by O. A. Demidova, V. V. Arkhipov, M. V. Zhuravleva, T. A. Alexandrova, A. A. Alexandrov

    Published 2020-12-01
    Get full text
    Article

    Save to List
    Saved in:
  19. 19
    Current Mesalazine Products: Differences in Enteric-Coated Dosage Forms and Pharmaceutical Risks of Clinical Efficacy Reduction (Review)

    Current Mesalazine Products: Differences in Enteric-Coated Dosage Forms and Pharmaceutical Risks of Clinical Efficacy Reduction (Review) by S. Yu. Serebrova, V. V. Evteev, E. Yu. Demchenkova, M. V. Zhuravleva, A. B. Prokofiev

    Published 2024-12-01
    Get full text
    Article

    Save to List
    Saved in:
  20. 20
    Comparative Analysis of Drug Interactions with Antibacterial Agents in the Treatment of Community-Acquired Pneumonia

    Comparative Analysis of Drug Interactions with Antibacterial Agents in the Treatment of Community-Acquired Pneumonia by A. A. Taube, M. V. Zhuravleva, T. V. Alexandrova, O. A. Demidova, I. A. Mazerkina

    Published 2021-10-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: